JelloX Biotech Expands to U.S. with New 3D Pathology Lab in Phoenix

In a move to accelerate technological innovation in cancer diagnostics, Taiwan-based JelloX Biotech Inc. has announced the opening of its first U.S. research facility within Discovery Oasis, a major biomedical development in Phoenix, Arizona.

The new lab will serve as a platform for advancing the company’s pioneering 3D pathology and AI-powered imaging technologies, supporting its mission to transform oncology diagnostics and treatment. Discovery Oasis, spanning 120 acres, is designed to foster collaboration between cutting-edge biotech companies focused on solving some of the world’s most complex healthcare challenges.

JelloX’s Phoenix lab will occupy approximately 1,100 square feet and be outfitted with its most sophisticated diagnostic equipment, dedicated to applying 3D digital pathology for cancer detection and management.

"Medical problems like cancer require many parties working together to create better treatments and patient care," commented Dr. Yen-Yin Lin, CEO of JelloX. "With all the promise 3D pathology offers, we are thrilled to establish a research base in the US, particularly one where we can work hand-in-hand with other pioneering companies to fight cancer while contributing to the country's leadership in biotech innovation."

Pushing the Boundaries of Cancer Diagnosis with 3D Pathology

JelloX is known for its development of advanced 3D pathology techniques, which offer significant advantages over traditional 2D tissue analysis. Unlike conventional histopathology that examines thin slices of tissue, JelloX’s 3D imaging allows for deeper, more detailed insights into tumor structures, improving diagnostic accuracy and enabling earlier detection.

"3D pathology can offer at least 50 times more information than conventional 2D methods, providing pathologists with a more comprehensive understanding of a tumor's biology," said Dr. Lin. "The power of such a diagnostic tool lies in its ability to help pathologists stratify and personalize, matching the right patients with the right treatment at the right time. This ultimately leads to better prognosis, quality of life, and more patient-centered care."

ADVERTISEMENT

JelloX’s technology has shown strong potential in clinical studies conducted in Japan and Taiwan, with applications across a variety of cancers, including colorectal, esophageal, and HER2-positive breast cancers. Its improved sensitivity has even reclassified prior false-negative cases, potentially altering the course of treatment for patients.

A Broad Impact on Healthcare Stakeholders

The company sees its innovations benefiting several sectors within the healthcare ecosystem:

• For physicians: Enhanced image data combined with AI integration helps reduce diagnostic workload and improve clinical decision-making.

• For pharmaceutical companies and researchers: The technology can refine companion diagnostics and serve as a powerful asset in new drug development.

• For healthcare systems: More accurate diagnostics can lead to more efficient resource use, reducing unnecessary costs and improving care delivery.

About JelloX Biotech Inc.

Headquartered in Hsinchu, Taiwan, JelloX Biotech is a forward-thinking company committed to revolutionizing cancer pathology using advanced 3D imaging and artificial intelligence. The company welcomes inquiries and partnerships at sales@jellox.com.

Learn more at: https://jellox.com/en/home/